Concomitant administration of a histamine2 receptor antagonist and proton pump inhibitor enhances gastric acid suppression

Pharmacotherapy

Volumn 35, Issue 12, 2015, Pages 1124-1129

  Abdul Hussein, Mustafa ^a   Freeman, Janice ^a   Castell, Donald ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

concomitant PPI and H2RA; gastric acid; GERD; H2RA; histamine2 receptor antagonist; PPI; proton pump inhibitor

Indexed keywords

OMEPRAZOLE; RANITIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH PH; COMBINATION DRUG THERAPY; GASTROESOPHAGEAL REFLUX; SECRETION (PROCESS); STOMACH ACID; TREATMENT OUTCOME;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RANITIDINE; TREATMENT OUTCOME;

EID: 84950969583     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1665     Document Type: Article

References (24)

1. Schubert ML, Peura DA,. Control of gastric acid secretion in health and disease. Gastroenterology 2008; 134: 1842-60.
2. Wolfe MM, Sachs G,. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118 (2 Suppl 1): S9-31.
3. Sachs G,. Physiology of the parietal cell and therapeutic implications. Pharmacotherapy 2003; 23 (10 Pt 2): 68S-73S.
4. Modlin IM, Sachs G, eds. Inhibition of the gastric acid pump. In: Acid related diseases: biology and treatment. Konstanz, Germany: Schnetztor-Verlag GmbH D-Konstanz, 1998: 126-45.
5. Shin J, Kim N,. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013; 19: 25-35.
6. Sachs G, Shin J, Hunt R,. Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep 2010; 12: 437-47.
7. De Graef J, Woussen-Colle MC,. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs. Gastroenterology 1986; 91: 333-7.
8. Im WB, Sih JC, Blakeman DP, McGrath JP,. Omeprazole, a specific inhibitor of gastric (H+- K+)-ATPase, is an H+-activated oxidizing agent of sulfhydryl groups. J Biol Chem 1985; 260: 4591-7.
9. Wolfe MM,. Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders. Up-to-date.
10. Fändriks L, Lönroth H, Pettersson A, Vakil N,. Can famotidine and omeprazole be combined on a once-daily basis? Scand J Gastroenterol 2007; 42: 689-94.
11. Bell NJY, Burget D, Howden CW, Wilkinson J, Hunt RH,. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 51: 59-67.
12. Ladas SD, Tassios PS, Raptis SA,. Selection of patients for successful maintenance treatment of esophagitis with low-dose omeprazole: use of 24-hour gastric pH monitoring. Am J Gastroenterol 2000; 95: 374-80.
13. Gosselin A, Luo R, Lohoues H, et al., The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health 2009; 12 (1): 34-39.
14. Hungin AP, Rubin G, O'Flanagan H,. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999; 49 (443): 463-4.
15. Sachs G,. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17: 22-37.
16. Hunt JN, Knox MT,. The slowing of gastric emptying by nine acids. J Physiol 1969; 201: 161-79.
17. Colin-Jones DG,. The role and limitations of H2-receptor antagonists in the treatment of gastro-esophageal reflux disease. Aliment Pharmacol Ther 1995; 9 (Suppl 1): 9-14.
18. Hannan A, Chesner I, Mann S, Walt R,. Can H2-antagonists alone completely block food stimulated acidity? Eur J Gastroenterol Hepatol 1991; 3: 533-7.
19. Merki HS, Wilder-Smith CH, Walt RP, Halter F,. The cephalic and gastric phases of gastric secretion during H2-antagonist treatment. Gastroenterology 1991; 101 (3): 599-606.
20. Ohsawa T, Hirata W, Higichi S,. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level. Int J Clin Pharmacol Res 2002; 22 (2): 29-35.
21. Deshpande A, Pant C, Pasupuleti V, et al., Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012; 10 (3): 225-33.
22. Yu EW, Bauer SR, Bain PA, Bauer DC,. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011; 124 (6): 519-26.
23. Cundy T, Dissanayake A,. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol 2008; 69 (2): 338-41.
24. Inadomi JM, McIntyre L, Bernard L, Fendrick AM,. Step-down from multiple-to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98 (9): 1940-4.